Navigation Links
PD-Rx Pharmaceuticals, Inc. Reports 1st Quarter Earnings
Date:12/4/2009

OKLAHOMA CITY, Dec. 4 /PRNewswire-FirstCall/ -- PD-Rx Pharmaceuticals, Inc. (Pink Sheets: PDRX) today announced revenue of $5,012,334 for the first quarter ended September 30, 2009, a 24% decrease over the same period last year. Operating income and net income for the quarter were $133,681 and $80,402, respectively, each a 70% decrease over the same period last year.

Results were impacted by a decrease in pharmacy sector sales. This trend is expected to continue throughout the rest of the fiscal year. In this economic environment, the company is focused on three main actions; working with customers to provide high value products at the lowest cost, increasing focus on expense management and targeting investment into the highest priority strategic opportunities.

ABOUT THE COMPANY:

PD-Rx offers pharmaceutical and management strategies to the healthcare industry. Our management strategies focus on new products, solid business partners, and the specialized segment of the pharmaceutical industry. As a licensed FDA manufacturer and packager, PD-Rx offers a full spectrum of medications and specialized services. Our goal is to develop a matrix of cost containment tools and products that we can merge into any healthcare network to enhance patient care and improve managed care organizations bottom line. We provide proprietary products and prepackaged medications that are viewed by patient, insurance payers and healthcare providers as a progressive and responsive practice.

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks and uncertainties or other factors, which may cause actual results, performance or achievements expressed or implied by such forward-looking statements to vary from those forecast or implied in this release. Factors that might cause such a difference include, without limitation, decline in demand for the company's products or services, and the effect of general economic conditions and factors affecting the industry.


Jack L. McCall, EVP & COO
Ph. 405-942-3040 / jlm@pdrx.com

SOURCE PD-Rx Pharmaceuticals, Inc.


'/>"/>
SOURCE PD-Rx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. PD-Rx Completes Call for Preferred A Stock
2. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
3. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
4. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
5. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
6. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
7. ACG Announces Major Gift by Salix Pharmaceuticals, Inc.
8. Anthera Pharmaceuticals, Inc. Appoints Donald Santel to Board of Directors
9. Elan Pharmaceuticals, Inc. Licenses Software and Databases From GeneGo
10. Jazz Pharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
11. Acura Pharmaceuticals, Inc. Announces Implementation of Reverse Stock Split and New Trading Symbol: ACPH
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... , ... As health professionals work to improve their approach to healthcare, there ... more than filling out a survey; in many cases health professionals and patients are ... care and research on the importance of active engagement with patients and members of ...
(Date:10/13/2017)... Las Vegas, Nevada (PRWEB) , ... October 13, 2017 , ... ... of 7® Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum ... CBD dose required and providing a CBD form that can be easily incorporated into ...
(Date:10/13/2017)... ... , ... Many families have long-term insurance that covers care for a family ... for care if the client has a cognitive impairment diagnosis. , “What this ... often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, owner ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... the most popular and least understood books in the Holy Scriptures, Revelation. The Book ... have baffled scholars for centuries. Many have tossed it off as mere rubbish, but ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “America On The ... identity. “America On The Brink” is the creation of published author, William Nowers. ... great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... WASHINGTON , Sept. 28, 2017 Cohen ... to advance the use of wearable and home sensors ... brain disorders. Early Signal Foundation, a nonprofit organization focused ... populations, will provide an affordable analytical system to record ... ...
(Date:9/25/2017)... PROVIDENCE, R.I. , Sept. 25, 2017 /PRNewswire/ ... immunogenicity assessment, vaccine design, and immune-engineering today announced ... focused on the development of personalized therapeutic cancer ... and has provided exclusive access to enabling technologies ... MSc Eng., MBA will lead EpiVax Oncology as ...
(Date:9/19/2017)... Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, ... tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek , PhD, ...
Breaking Medicine Technology: